The event: Phase III efficacy studies of Libigel for the treatment of female sexual dysfunction.
The timeline: Top-line results expected in the fall.
The stakes: A female Viagra, sort of. BioSante is trying to succeed where other drug companies have failed -- to be the first company to receive U.S. approval for a drug to boost the sexual "desire" of post-menopausal women.
BioSante is conducting three phase III studies of Libigel. The first two randomized, placebo-controlled trials are designed to show that Libigel increases sexual desire and the frequency of satisfying sexual events in surgically menopausal women. BioSante is also running a third phase III study designed to demonstrate Libigel's long-term safety.